pioglitazone has been researched along with ADPKD in 3 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pioglitazone target PPARγ was expressed at surprisingly low levels in mouse, rat and human kidneys." | 5.56 | Renal cyst growth is attenuated by a combination treatment of tolvaptan and pioglitazone, while pioglitazone treatment alone is not effective. ( Bange, H; Dijkstra, KL; Kanhai, AA; Leonhard, WN; Peters, DJM; Price, LS; Verburg, L, 2020) |
| "The pathology of ADPKD is complex and involves the malfunction of different signaling pathways like cAMP, Hedgehog, and MAPK/ERK pathway owing to the mutated product that is polycystin-1 or 2." | 2.66 | Autosomal dominant polycystic kidney disease and pioglitazone for its therapy: a comprehensive review with an emphasis on the molecular pathogenesis and pharmacological aspects. ( Saini, AK; Saini, R; Singh, S, 2020) |
| "The pioglitazone target PPARγ was expressed at surprisingly low levels in mouse, rat and human kidneys." | 1.56 | Renal cyst growth is attenuated by a combination treatment of tolvaptan and pioglitazone, while pioglitazone treatment alone is not effective. ( Bange, H; Dijkstra, KL; Kanhai, AA; Leonhard, WN; Peters, DJM; Price, LS; Verburg, L, 2020) |
| "Treatment with pioglitazone improved survival of Pkd1(-/-) embryos and ameliorated the cardiac defects and the degree of renal cystogenesis." | 1.31 | Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. ( Aiba, A; Harris, PC; Higashihara, E; Horie, S; Katsuki, M; Kitamura, T; Kurabayashi, M; Muto, S; Nagai, R; Nakamura, K; Nakao, K; Saito, Y; Tomita, K, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Kanhai, AA | 1 |
| Bange, H | 1 |
| Verburg, L | 1 |
| Dijkstra, KL | 1 |
| Price, LS | 1 |
| Peters, DJM | 1 |
| Leonhard, WN | 1 |
| Saini, AK | 1 |
| Saini, R | 1 |
| Singh, S | 1 |
| Muto, S | 1 |
| Aiba, A | 1 |
| Saito, Y | 1 |
| Nakao, K | 1 |
| Nakamura, K | 1 |
| Tomita, K | 1 |
| Kitamura, T | 1 |
| Kurabayashi, M | 1 |
| Nagai, R | 1 |
| Higashihara, E | 1 |
| Harris, PC | 1 |
| Katsuki, M | 1 |
| Horie, S | 1 |
1 review available for pioglitazone and ADPKD
| Article | Year |
|---|---|
Autosomal dominant polycystic kidney disease and pioglitazone for its therapy: a comprehensive review with an emphasis on the molecular pathogenesis and pharmacological aspects.
Topics: Animals; Biomarkers; Disease Management; Gene Expression Regulation; Genetic Association Studies; Ge | 2020 |
2 other studies available for pioglitazone and ADPKD
| Article | Year |
|---|---|
Renal cyst growth is attenuated by a combination treatment of tolvaptan and pioglitazone, while pioglitazone treatment alone is not effective.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Cell Culture Techniques; Combined Modality Thera | 2020 |
Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant.
Topics: Animals; beta Catenin; Cytoskeletal Proteins; Endothelium; Kidney; Mice; Phenotype; Pioglitazone; Po | 2002 |